BTAI BioXcel Therapeutics Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Yocca Frank	2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [ BTAI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Scientific Officer
(Last)          (First)          (Middle) C/O BIOXCEL THERAPEUTICS, INC.,, 555 LONG WHARF DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 2/14/2020
(Street) NEW HAVEN, CT 06511 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	2/14/2020		M		80000	A	$0.41	88397	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.41	2/14/2020		M			80000	(1)	8/23/2027	Common Stock	80000	$0	69310	D
Stock Option	$11							(2)	3/12/2028	Common Stock	36498		36498 (3)	D

Explanation of Responses:
(1)	The option is vested and became exercisable with respect to 10,146 shares and, with respect to the remaining 59,164 shares, will vest equally over the next 19 months from February 22, 2020 through August 22, 2021.
(2)	The option is vested and became exercisable with respect to 17,488 shares and, with respect to the remaining 19,010 shares, will vest equally over the next 25 months from March 12, 2020 through March 22, 2022.
(3)	The total number of derivative securities beneficially owned following reported transaction was incorrectly stated on the Form 4 filed by the reporting person on March 13, 2018, and is corrected with this report.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Yocca Frank C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE NEW HAVEN, CT 06511			Chief Scientific Officer

Signatures
/s/ Frank Yocca		2/19/2020
**Signature of Reporting Person		Date